Abstract

Although kidney transplantation remains the best treatment for end-stage renal failure, it is limited by chronic humoral aggression of the graft vasculature by donor-specific antibodies (DSAs). The complement-independent mechanisms that lead to the antibody-mediated rejection (ABMR) of kidney allografts remain poorly understood. Increasing lines of evidence have revealed the relevance of natural killer (NK) cells as innate immune effectors of antibody-dependent cellular cytotoxicity (ADCC), but few studies have investigated their alloreactive potential in the context of solid organ transplantation. Our study aimed to investigate the potential contribution of the antibody-dependent alloreactive function of NK cells to kidney graft dysfunction. We first conducted an observational study to investigate whether the cytotoxic function of NK cells is associated with chronic allograft dysfunction. The NK-Cellular Humoral Activation Test (NK-CHAT) was designed to evaluate the recipient and antibody-dependent reactivity of NK cells against allogeneic target cells. The release of CD107a/Lamp1+ cytotoxic granules, resulting from the recognition of rituximab-coated B cells by NK cells, was analyzed in 148 kidney transplant recipients (KTRs, mean graft duration: 6.2 years). Enhanced ADCC responsiveness was associated with reduced graft function and identified as an independent risk factor predicting a decline in the estimated glomerular filtration rate over a 1-year period (hazard ratio: 2.83). In a second approach, we used the NK-CHAT to reveal the cytotoxic potential of circulating alloantibodies in vitro. The level of CD16 engagement resulting from the in vitro recognition of serum-coated allogeneic B cells or splenic cells was further identified as a specific marker of DSA-induced ADCC. The NK-CHAT scoring of sera obtained from 40 patients at the time of transplant biopsy was associated with ABMR diagnosis. Our findings indicate that despite the administration of immunosuppressive treatments, robust ADCC responsiveness can be maintained in some KTRs. Because it evaluates both the Fab recognition of alloantigens and Fc-driven NK cell activation, the NK-CHAT represents a potentially valuable tool for the non-invasive and individualized evaluation of humoral risk during transplantation.

Highlights

  • Kidney transplantation is the best treatment for patients with endstage chronic kidney disease (CKD)

  • A multivariate Cox regression analysis of the factors associated with CKD progression further indicated that this intermediate level of the antibody-dependent cellular cytotoxicity (ADCC) responsiveness observed in kidney transplant recipients (KTRs) (CD107a/Lamp1URI > 3) was associated with the occurrence of graft function decline (≥10% estimated glomerular filtration rate (eGFR) loss) or graft failure in 34% of the transplanted recipients during the mean follow-up period of 13.3 months (Figure 2C and Table 2)

  • Independently of the detection of circulating donor-specific antibodies (DSAs), the individualized natural killer (NK)-CHAT scoring of peripheral NK cell activity may provide relevant information concerning complement-independent mechanisms that favor the development of chronic allograft injury

Read more

Summary

Introduction

Kidney transplantation is the best treatment for patients with endstage chronic kidney disease (CKD). De novo donor-specific antibodies (dnDSA) have been identified as major contributors to chronic ABMR and have been associated with graft microvascular injury [6,7,8,9] and arterial intimal fibrosis [10, 11]. The NK cell molecular signatures from transplant biopsies of patients with ABMR [32, 34,35,36,37] suggest that NK cell activation is associated with humoral allograft vasculopathy [38, 39]. NK cells are known cytotoxic effectors of the innate immune responses to antibodies, their potential pathogenic role in transplant rejection remains poorly documented.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call